Association of annexin A2 with cancer development (Review)

Xu, Xiaofei; Pan, Wei; Kang, Lihua; Feng, Hui; Song, Yanqiu

doi:10.3892/or.2015.3837

Cited by 67 publications

(64 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Annexin A2 orchestrates multiple biological processes and clinical associations, particularly during cancer progression (16). It has been demonstrated that Annexin A2 dysregulation is associated with the onset, invasion, metastasis and drug resistance of cancer (17).…”

Section: Discussionmentioning

confidence: 99%

Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

Luo

Xie

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Due to the lack of a definite diagnosis, a frequent recurrence rate and resistance to chemotherapy or radiotherapy, the clinical outcome for patients with advanced laryngeal cancer has not improved over the last decade. Annexin A2 is associated with the invasion and metastasis of cancer cells. In the present study, it was demonstrated using differential proteomics analysis that Annexin A2 is highly expressed in laryngeal carcinoma tissues and this was confirmed using immunohistochemistry, which demonstrated that the expression of Annexin A2 in laryngeal carcinoma tissues was significantly higher than in healthy adjacent tissue. In addition, its potential predictive value in the prognosis of patients with laryngeal carcinoma was evaluated. The results demonstrated that Annexin A2 expression was significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage. In addition, higher Annexin A2 expression was associated with a poor prognosis of patients with laryngeal cancer. Thus, the results of the present study indicate that Annexin A2 expression is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

Luo

Xie

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…In present study, we used the combination of co-IP and MS to identify 6 molecular partners of UBAP2, including Annexin A2. Accumulating evidence have showed that Annexin A2 is aberrantly expressed in a wide spectrum of cancers, including HCC [15-17]. Annexin A2 involved in several pathological processes, such as tumor cell adhesion, proliferation, apoptosis, tumor neoangiogenesis, invasion and metastasis [15, 16].…”

Section: Discussionmentioning

confidence: 99%

UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2

Bai

Long

et al. 2016

Oncotarget

View full text Add to dashboard Cite

The ubiquitin-dependent proteasomal degradation of proteins controls signaling and cellular survival. In this study, we found that ubiquitin associated protein 2 (UBAP2) was significantly downregulated in hepatocellular carcinoma (HCC) tissues compared with adjacent normal tissues. Furthermore, higher expression of UBAP2 in cancer tissues was correlated with good prognosis in HCC patients. Knockdown of UBAP2 significantly enhanced the invasion and proliferation of HCC cells in vitro and promoted tumor growth in vivo, while enforced expression of UBAP2 impaired the aggressive ability and tumor growth of HCC cells. Mechanistically, UBAP2 formed a complex with Annexin A2 and promoted the degradation of Annexin A2 protein by ubiquitination, and then inhibited HCC progression. Collectively, UBAP2 appears as a novel marker for predicting prognosis and a therapeutic target for HCC.

show abstract

“…ANXA2 is overexpressed in numerous tumours, including glioma . Aberrantly, expression of ANXA2 plays important roles in tumour development by regulating cell proliferation, apoptosis, invasion and metastasis …”

Section: Introductionmentioning

confidence: 99%

S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF‐κB positive feedback loop

Xie

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most universal type of primary brain malignant tumour, and the prognosis of patients with GBM is poor. S100A11 plays an essential role in tumour. However, the role and molecular mechanism of S100A11 in GBM are not clear. Here, we found that S100A11 was up‐regulated in GBM tissues and higher S100A11 expression indicated poor prognosis of GBM patients. Overexpression of S100A11 promoted GBM cell growth, epithelial‐mesenchymal transition (EMT), migration, invasion and generation of glioma stem cells (GSCs), whereas its knockdown inhibited these activities. More importantly, S100A11 interacted with ANXA2 and regulated NF‐κB signalling pathway through decreasing ubiquitination and degradation of ANXA2. Additionally, NF‐κB regulated S100A11 at transcriptional level as a positive feedback. We also demonstrated the S100A11 on tumour growth in GBM using an orthotopic tumour xenografting. These data demonstrate that S100A11/ANXA2/NF‐κB positive feedback loop in GBM cells that promote the progression of GBM.

show abstract

Association of annexin A2 with cancer development (Review)

Cited by 67 publications

References 144 publications

Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2

S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF‐κB positive feedback loop

Contact Info

Product

Resources

About